Literature DB >> 32491073

The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.

Lutfu Askin1, Okan Tanrıverdi1, Husna Sengul Askin2.   

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32491073     DOI： 10.36660/abc.20200273

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN： 0066-782X            Impact factor:   2.000


  5 in total

1.  MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19.

Authors:  Valéria Bumiller-Bini; Camila de Freitas Oliveira-Toré; Tamyres Mingorance Carvalho; Gabriela Canalli Kretzschmar; Letícia Boslooper Gonçalves; Nina de Moura Alencar; Miguel Angelo Gasparetto Filho; Marcia Holsbach Beltrame; Angelica Beate Winter Boldt
Journal:  Genet Mol Biol       Date:  2021-03-17       Impact factor: 1.771

2.  Prevalence and Associated Factors of SARS caused by Covid-19 in Adults and Aged People with Chronic Cardiovascular Disease: A Critical AnalysisReplyPrevalence and Associated Factors of SARS by Covid-19 in Adults and Aged People with Chronic Cardiovascular DiseaseDo Underlying Cardiovascular Diseases Have any Impact on Hospitalised Patients with COVID-19?Cardiovascular Diseases Burden in COVID-19: Systematic Review and Meta-AnalysisPrevalence of Cardiovascular Risk Factors and Other Comorbidities in Patients with Hypertension in Portuguese Primary Health Care Populations: The PRECISE StudyWorldwide Trends in Hypertension Prevalence and Progress in Treatment and Control from 1990 to 2019: A Pooled Analysis of 1201 Population-Representative Studies with 104 Million ParticipantsBenefits and Limitations of Implementing Chronic Care Model (CCM) in Primary Care Programs: A Systematic Review.

Authors:  Fernanda Gunha Ignácio; Fernanda Pinzon Ribeiro; Aline Oenning Baggio; Chaiana Esmeraldino Mendes Marcon
Journal:  Arq Bras Cardiol       Date:  2022-04       Impact factor: 2.000

3.  How Can the Presence of Cardiovascular Diseases Impact Morbidity and Mortality in Patients with COVID-19?

Authors:  Alexandre de Matos Soeiro
Journal:  Arq Bras Cardiol       Date:  2022-05       Impact factor: 2.667

4.  Burden and prevalence of risk factors for severe COVID-19 disease in the ageing European population - A SHARE-based analysis.

Authors:  Linda Juel Ahrenfeldt; Camilla Riis Nielsen; Sören Möller; Kaare Christensen; Rune Lindahl-Jacobsen
Journal:  Res Sq       Date:  2020-09-09

5.  Prevalence and Associated Factors of SARS by Covid-19 in Adults and Aged People with Chronic Cardiovascular Disease.

Authors:  Karina Mary de Paiva; Danúbia Hillesheim; Cassiano Ricardo Rech; Rodrigo Sudatti Delevatti; Rodrigo Vasconi Sáez Brown; Ana Inês Gonzáles; Patricia Haas
Journal:  Arq Bras Cardiol       Date:  2021-11       Impact factor: 2.000
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.